Hospira is now officially a part of Pfizer and today marks the first day operating as a combined business. The One 2 One parenteral contract development and manufacturing business will continue its operation alongside Pfizer’s existing contract manufacturing business, Pfizer CentreSource. The global market value for both generic sterile injectables and biosimilars is expected to grow, estimated to be $70 billion and $20 billion in 2020, respectively. The acquisition expands Pfizer’s portfolio...